Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21483

Shown on this page

Current sort

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Head and Neck Cancers
Interventions: Handheld cough device; Device
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed; Drug
Lead sponsor: BlossomHill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: RO7204239, Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Interventions: CTX-8371; Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • Margate, Florida + 8 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Interventions: Cyclophosphamide, Docetaxel, Medical Chart Review, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • Rochester, New York

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more

Conditions: Obesity, Adolescent, Oxytocin
Interventions: Oxytocin nasal spray, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 10 Years to 18 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Interventions: Danicamtiv; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Interventions: Pirtobrutinib, Venetoclax, Rituximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: REGN5678, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 24
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Clinical trials in Boston, Massachusetts

Filter and sort this location

Institutions in Boston

Live official records

Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Oxytocin for Weight Loss in Adolescents

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors